- Solaxa and Alvogen enter into license agreement for the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B)
- Alvogen will acquire worldwide rights for SLX-100 for SCA27B and will be responsible for the commercialization of SLX-100 in the U.S. and global markets
- Solaxa will receive an upfront payment, and be eligible to receive development, regulatory and sales milestone payments, totaling $95 million in the aggregate, as well as double-digit royalties on net sales
Morristown, NJ and Bethesda, MD, February 23, 2026 — Alvogen, a US-based wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (TWSE: 1795) focused on developing, in-licensing, manufacturing and marketing pharmaceutical products, and Solaxa Inc., a biopharmaceutical public benefit corporation focused on rare neurological conditions, today announced a global license agreement covering the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B) for global markets.
Under the terms of the agreement, Solaxa is entitled to receive an initial payment to support registrational studies in SCA27B, and is eligible to receive additional payments upon the achievement of certain development milestones, upon receipt of FDA approval for SLX-100, and based on reaching certain net sales thresholds, totaling up to $95 million in the aggregate. In addition to milestone payments, Solaxa is eligible to receive double-digit royalties on net sales.
Alvogen will obtain the worldwide rights for SLX-100 for the treatment of SCA27B. Alvogen will also be responsible for the commercialization of SLX-100 across global markets, including commercialization in the U.S. market which Alvogen expects to lead through its Almatica label. Almatica is the CNS-focused subsidiary of Alvogen that currently markets branded products.
Kerry Clem, Chief Executive Officer of Solaxa, commented, “We are thrilled to partner with Alvogen on the development of SLX-100 for patients living with spinocerebellar ataxia. This collaboration has the potential to meaningfully accelerate our ability to deliver a much-needed therapy to individuals facing this debilitating condition. Alvogen’s deep expertise in CNS disorders, combined with its expanding global capabilities, makes them an exceptional partner as we work to bring new hope to the SCA27B community.”
Divya Patel, Chief Executive Officer of Alvogen commented, “We are excited to partner with Solaxa to advance SLX-100 for patients living with SCA27B, a rare condition with significant unmet medical need. This agreement further strengthens our central nervous system portfolio and reflects our commitment to expanding innovative treatment options in neurology. Through our experienced U.S. commercial organization and established CNS-focused infrastructure, we are well positioned to support the successful launch of SLX-100.”
Patients identified as having SCA27B, a rare hereditary ataxia caused by GAA repeat expansion in the FGF14 gene, represent a subset of the broader population living with the symptoms of spinocerebellar ataxia. While precise population-level prevalence is still being defined following its initial characterization in January 2023, SCA27B has emerged as a meaningful contributor to previously unexplained adult-onset ataxia. There are currently no FDA-approved therapies specifically for SCA27B or any other spinocerebellar ataxia, underscoring the significant unmet medical need for targeted treatment options.
SLX-100 is uniquely positioned to be first-to-market with strong patient advocacy and regulatory support, including FDA orphan drug designation. Solaxa plans to initiate registrational studies by mid-year 2026, with results from the study expected to support a new drug application filing for SCA27B in 2027.
About Solaxa
Solaxa is a clinical-stage biopharmaceutical public benefit corporation developing treatments that restore nerve function in patients with rare neurodegenerative diseases and acute nerve injuries. The company is developing a class of aminopyridine drugs that both detect and treat ion channel dysfunction. Solaxa’s public benefit mission is to advance scientific knowledge and deliver impactful and accessible therapies that improve outcomes for patients worldwide.
About Alvogen
Alvogen is a US-based wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. focused on developing, in-licensing, manufacturing and marketing pharmaceutical products. The company has a diverse portfolio and pipeline that includes both branded and generic products across various administration forms. The Alvogen-family of companies includes Alvogen (Generics), Almatica (Brands) and Almaject (Injectables).
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com